ICLUSIG DIN 02437333
Status: Marketed
Holder: TAKEDA PHARMACEUTICALS U.S.A., INC.
Molecule: PONATINIB (PONATINIB HYDROCHLORIDE)
Available to quote
Health Canada record
| Active ingredient(s) | PONATINIB (PONATINIB HYDROCHLORIDE) 15 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01EA05 PONATINIB |
| Original market date | 21-Aug-2015 |
| Current status date | 29-Jun-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Takeda Pharmaceutical Company Limited — licence , not currently licensed, last inspection rating C (2023-12-11).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing PONATINIB (PONATINIB HYDROCHLORIDE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02437341 | ICLUSIG | TAKEDA PHARMACEUTICALS U.S.A., INC. | Tablet | PONATINIB (PONATINIB HYDROCHLORIDE) 45 MG | Dormant |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 28710 | 2022-08-08 | New Drug Submission (NDS) | Administrative: Merger/Buy-out |
| 16753 | 2015-04-02 | New Drug Submission (NDS) |